TheJakartaPost
Please Update your browser
Your browser is out of date, and may not be compatible with our website. A list of the most popular web browsers can be found below.
Just click on the icons to get to the download page.
Government resumes use of AstraZeneca vaccines after clot scare
The Food and Drug Monitoring Agency (BPOM) cleared a batch of the vaccine on Thursday, ending a suspension of its use after reports linking the vaccine with rare blood clots.
Change text size
Gift Premium Articles
to Anyone
Share the best of The Jakarta Post with friends, family, or colleagues. As a subscriber, you can gift 3 to 5 articles each month that anyone can read—no subscription needed!
A police officer stands guard near a shipping container containing COVID-19 vaccines produced by AstraZeneca at Soekarno-Hatta International Airport in Tangerang, Banten, on May 8. Indonesia received 1.3 million doses of the AstraZeneca vaccine under the COVAX facility, a multilateral effort that aims for equal global access to vaccines. (Antara/Fauzan)
The government has resumed COVID-19 vaccinations using the suspended batch of AstraZeneca vaccine after investigating reports that it may have caused blood clot among some recipients.
The Health Ministry welcomed on Thursday the findings of the Food and Drug Monitoring Agency (BPOM), according to which the vaccine batch was “safe to use” and the suspension would be lifted.
“Batch CTMAV547 of the AstraZeneca COVID-19 vaccine can continue to be used in the national vaccination program,” ministry spokeswoman Siti Nadia Tarmizi said in a press statement.
Earlier this month, the ministry had halted the distribution of almost half a million doses of the vaccine for investigation purposes, following reports of three deaths allegedly linked to the vaccine.
Investigations on the toxicity and sterility of the batch were carried out by the BPOM, the state body responsible for authorizing the nationwide use of the vaccine in March.
